Anthony Cucci, MD
Pulmonary Disease · Akron, OHNPI 1629364690
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $191,030 of the $263,652 with a category attached, or 72.5%. United Therapeutics Corporation accounts for 97.5% of it on its own, with 8 other manufacturers making up the rest. Among pulmonary disease clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 353 payments — averaging $746.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$257K
- Chiesi USA, Inc.$5K
- Insmed, Inc.$789
- Actelion Pharmaceuticals US, Inc.$276
- Merck$53
- Abiomed$44
- plus $72 from 3 others
What the payments were for
- Consulting fees$33,97913%
- Speaking & faculty fees$191,03072%
- Travel & lodging$28,74211%
- Food & beverage$9,8394%
- Education$620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 328 | $257,152 |
| Chiesi USA, Inc. | 7 | $5,267 |
| Insmed, Inc. | 7 | $789 |
| Actelion Pharmaceuticals US, Inc. | 4 | $276 |
| Merck | 2 | $53 |
| Abiomed | 1 | $44 |
| GSK | 2 | $31 |
| Liquidia Technologies, Inc. | 1 | $27 |
| AstraZeneca | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$263,652 in reported general payments places this provider in the 95th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 104 | $2,442,179 |
| OpsumitMacitentan | 52 | $653,819 |
| WinrevairSotatercept-Csrk | 17 | $339,936 |
| Tadalafil | 93 | $98,268 |
| Spiriva RespimatTiotropium Bromide | 114 | $81,637 |
| Sildenafil Citrate | 163 | $71,249 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 91 | $53,456 |
| EliquisApixaban | 67 | $50,762 |
| Breo ElliptaFluticasone/Vilanterol | 58 | $38,387 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $34,722 |
| Ambrisentan | 11 | $33,824 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 49 | $27,755 |
| Spiriva HandihalerTiotropium Bromide | 28 | $18,008 |
| DuleraMometasone/Formoterol | 40 | $16,471 |
| Incruse ElliptaUmeclidinium Bromide | 38 | $13,065 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $276 | $653,81952 claims |
| MerckWinrevair, Dulera | $53 | $356,40757 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $31 | $113,930191 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $15 | $16,08332 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Akron
- Joseph KhabbazaAkron$655K
- Mohammad KhanAkron$388K
- Aliaksandr RamaniukAkron$41K
- Amit DiwakarAkron$24K
- Robert BaughmanCincinnati$640K
- Kristin HighlandCleveland$551K
- Bruce CorserCincinnati$502K
- Jason StieneckerLima$397K
- Mohammad SheattCincinnati$389K
- Thomas YungerDayton$353K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.